Cargando…
Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients
BACKGROUND: This real-life study aimed to assess omalizumab treatment patterns in adult and paediatric asthma patients, and to describe asthma control and healthcare resource use (HCRU) at omalizumab initiation and discontinuation. METHODS: The French healthcare database system (Système National des...
Autores principales: | Humbert, Marc, Bourdin, Arnaud, Taillé, Camille, Kamar, Driss, Thonnelier, Céline, Lajoinie, Audrey, Rigault, Alexandre, Deschildre, Antoine, Molimard, Mathieu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647070/ https://www.ncbi.nlm.nih.gov/pubmed/35618272 http://dx.doi.org/10.1183/13993003.03130-2021 |
Ejemplares similares
-
Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study
por: Just, Jocelyne, et al.
Publicado: (2021) -
Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study
por: Humbert, Marc, et al.
Publicado: (2018) -
Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL
por: Menzella, Francesco, et al.
Publicado: (2023) -
Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma
por: Hanania, Nicola A., et al.
Publicado: (2022) -
Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme
por: Taillé, Camille, et al.
Publicado: (2020)